Skip to main content

Table 1 Summary of the clinical parameters of patients with Crohn's disease

From: Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease

  Responders Non-responders Responders Non-responders  
  Test cohort Validation cohort Difference
At baseline 14 6 13 7  
Gender (male/female) 8/6 4/3 8/5 4/4  
Age (years) 36.2±14.6 36±15.4 26.8±8.7 30.2±5.1 Non-significant
CDAI 319.6±41.3 351.5±33.1 338.3±61.7 370.7±48.1 Non-significant
CRP (mg/ml) 22.7±20.2 13.5±28.9 27.2±36.2 16.5±11.6 Non-significant
Hemoglobin (g/l) 125.1±17.6 120.6±27.6 130±17.9 127±12 Non-significant
Leukocytes(g/l) 9±3.3 8±3.1 7.5±2.3 9.2±2.8 Non-significant
Neutrophils (%) 70±8.9 74.5±8.9 74±8.1 72.8±5.7 Non-significant
  1. CDAI, Crohn's disease activity index; CRP, C-reactive protein. Data are shown as mean ±SD.